S
Sharyn D. Baker
Researcher at Ohio State University
Publications - 284
Citations - 13815
Sharyn D. Baker is an academic researcher from Ohio State University. The author has contributed to research in topics: Pharmacokinetics & Myeloid leukemia. The author has an hindex of 67, co-authored 260 publications receiving 12638 citations. Previous affiliations of Sharyn D. Baker include University of Texas Health Science Center at San Antonio & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
The genomic landscape of hypodiploid acute lymphoblastic leukemia
Linda Holmfeldt,Lei Wei,Ernesto Diaz-Flores,Michael Walsh,Jinghui Zhang,Li Ding,Debbie Payne-Turner,Michelle L. Churchman,Anna Andersson,Shann Ching Chen,Kelly McCastlain,Jared Becksfort,Jing Ma,Gang Wu,Samir Patel,Susan L. Heatley,Letha A. Phillips,Guangchun Song,John Easton,Matthew Parker,Xiang Chen,Michael Rusch,Kristy Boggs,Bhavin Vadodaria,Erin Hedlund,Christina D. Drenberg,Sharyn D. Baker,Deqing Pei,Cheng Cheng,Robert Huether,Charles Lu,Robert S. Fulton,Lucinda Fulton,Yashodhan Tabib,David J. Dooling,Kerri Ochoa,Mark D. Minden,Ian D. Lewis,L. Bik To,Paula Marlton,Andrew W. Roberts,Gordana Raca,Wendy Stock,Geoffrey Neale,Hans G. Drexler,Ross A. Dickins,David W. Ellison,Sheila A. Shurtleff,Ching-Hon Pui,Raul C. Ribeiro,Meenakshi Devidas,Andrew J. Carroll,Nyla A. Heerema,Brent L. Wood,Michael J. Borowitz,Julie M. Gastier-Foster,Julie M. Gastier-Foster,Susana C. Raimondi,Elaine R. Mardis,Richard K. Wilson,James R. Downing,Stephen P. Hunger,Mignon L. Loh,Charles G. Mullighan +63 more
TL;DR: Both near-haploid and low-hypodiploid leukemic cells show activation of Ras-signaling and phosphoinositide 3-kinase (PI3K)-signaling pathways and are sensitive to PI3K inhibitors, indicating that these drugs should be explored as a new therapeutic strategy for this aggressive form of leukemia.
Journal ArticleDOI
CREBBP mutations in relapsed acute lymphoblastic leukaemia
Charles G. Mullighan,Jinghui Zhang,Lawryn H. Kasper,Stephanie Lerach,Debbie Payne-Turner,Letha A. Phillips,Susan L. Heatley,Linda Holmfeldt,J. Racquel Collins-Underwood,Jing Ma,Kenneth H. Buetow,Ching-Hon Pui,Sharyn D. Baker,Paul K. Brindle,James R. Downing +14 more
TL;DR: Analysis of an extended cohort of 71 diagnosis–relapse cases and 270 acute leukaemia cases that did not relapse found that 18.3% of relapse cases had sequence or deletion mutations of CREBBP, which encodes the transcriptional coactivator and histone acetyltransferase CREB-binding protein (CREBBP).
Journal ArticleDOI
Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes
TL;DR: The differential metabolizing enzyme profiles suggest that there may be differences in drug-drug interaction potential and that stimulation of CYP3A4 may likely play a role in drug interactions for erlotinib and gefitinib.
Journal ArticleDOI
Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001
Sharyn D. Baker,Jaap Verweij,Eric K. Rowinsky,Ross C. Donehower,Jan H.M. Schellens,Louise B. Grochow,Alex Sparreboom +6 more
TL;DR: It is concluded that body surface area should not be used to determine starting doses of investigational agents in future phase I studies and alternate dosing strategies should be evaluated.
Journal Article
Irinotecan Pathway Genotype Analysis to Predict Pharmacokinetics
Ron H.J. Mathijssen,Sharon Marsh,Mats O. Karlsson,Rujia Xie,Sharyn D. Baker,Jaap Verweij,Alex Sparreboom,Howard L. McLeod +7 more
TL;DR: It is concluded that genotyping for ABCB1 1236C>T may be one of the factors assisting with dose optimization of irinotecan chemotherapy in cancer patients and additional investigation is required to confirm these findings in a larger population.